

Ref. No.: LASA/SE/17-18/014

Monday November 27, 2017

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Dear Sir,

Sub. : Press Release


With reference to the above subject, please find enclosed Press release of our Company titled “Begins trial production at Unit IV”

Request you to take the same on record and acknowledge receipt.

Thanking you,

Yours Truly,

Thanking you
For **LASA SUPERGENERICS LIMITED**


OMKAR P. HELRLEKAR
CHAIRMAN AND MANAGING DIRECTOR
DIN : 01587154





Lasa Supergenerics Limited

CIN: U24233MH2016PLC274202

-Media Release

Begins trial production at Unit IV (erstwhile known as Unit V)

Manufacture key Vet APIs

Regular production subject to successful trial runs

Mumbai, November 27, 2017: Lasa Supergenerics Limited (BSE: 540702, NSE: LASA), pioneer and amongst the leading player in manufacturing of Veterinary APIs in India through its catalyst chemistry expertise and fully backward integrated unit, announced that the Company has commenced the trial production at Unit IV, situated at Chiplun. The Unit IV was earlier known as Unit V. Now that we have overcome challenges and the Company is geared up to advantage of this significant opportunity and expand in lines with their strategic plans.

Please find below the actual photographs of the ceremony for the commencement of the unit -



The planned production and capacity per annum includes Albendazole Intermediate (400 MT), Fenbendazole Intermediate (200 MT), 2 4 DCP (600 MT), Closantel Intermediate (100 MT) and additionally a few components of backward integration for its recent new launches. Few marquee investors were also present there to commemorate the commencement of production process.



Lasa Supergenerics Limited

CIN: U24233MH2016PLC274202

The regular production will be subject to success of the trial runs.

Management Comments:

Commenting on the recent development, Mr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said:

"We are very happy to announce the commencement of trial production at Unit IV at Chiplun. This marks a great achievement for us as we have been able to start this facility after facing a lot of challenges, which give us further confidence to continue, with the already hard work and inputs that we have invested in this unit. We will continue to concentrate on manufacturing existing APIs from this facility. At the same time, we will continue with our strategy of backward integration, that has yielded us rich dividends. This has enabled us to tide over volatility due to raw material price fluctuations and cut our dependence on our suppliers. We have been working tirelessly after Lasa came into existence as an independent company. The Company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines. I thank the entire team of 'LASA' for their untiring efforts, hard work, sincerity and high dedication. Also, I would like to thank our valued Shareholders, whose support and faith in our Company has given us the determination and ambition to go from strength to strength."

About Lasa Supergenerics Limited:

Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. The Company is a pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. It specialises in 'catalyst chemistry' and manufactures anthelmintic/ veterinary API. To efficiently control the supply chain, the company has backward integrated its key molecules. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra. The Company exports APIs to countries like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more details please visit: www.lasalabs.com

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*